TOP NEWS

MabVax Therapeutics Looks To Sell Company In $3.7M Bankruptcy

San Diego-based biopharmaceuticals developer Mabvax, which filed for Chapter 11 bankruptcy in March, has lined up a buyer for the company, in a deal worth $3.7M. Mabvax filed for bankruptcy in March, login in order to access this members-only content, or become a member.